Choose Language

"Dedicated to giving our patients a promise for tomorrow"

BCG and ALT-803 for Non-Muscle Invasive Bladder Cancer

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

NYU Winthrop  Hospital Department of Urology is conducting this clinical research study for men and women ages 18 and older who have biopsy proven Non-Muscle Invasive Bladder Cancer.  This study will evaluate the safety and efficacy of a drug called ALT-803 and Bacillus Calmette-Guerin (BCG) combination therapy in treating patients with Non-Muscle Invasive Bladder Cancer (bladder cancer that has not spread into the muscles of the bladder).  Participants will be randomly assigned to receive ALT-803 and BCG therapy or BCG therapy alone.  The drugs will be inserted into the bladder through a catheter (a tube inserted into the bladder).
To be eligible for this clinical research study you must:
·         Biopsy confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma subtype, intermediate or high-risk
·         Have adequate heart, lung, liver and kidney functions
For more information, you can read about this study on by searching for identifier NCT02138734 or contact our research coordinator at 516-535-1900 or

Long Island Web Design